Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The clinical evidence from the POLARIX trial indicates that polatuzumab vedotin with R-CHP provides a moderate benefit over the standard R-CHOP treatment, particularly in terms of progression-free survival (PFS). The 24-month PFS rate was 76.7% for the treatment group compared to 70.2% for R-CHOP, with a hazard ratio of 0.73 (p=0.02). However, the overall survival benefit remains uncertain, as the trial did not demonstrate a statistically significant difference in overall survival rates, which limits the strength of the clinical effectiveness claim.
Cost effectiveness
The cost-effectiveness estimates for polatuzumab vedotin with R-CHP are likely to fall within NICE’s acceptable range of £20,000 to £30,000 per QALY gained. The committee concluded that the updated base case ICER was appropriate for decision-making, indicating a clear cost-effective profile under the commercial arrangement provided by the company.
Quality of life
The evidence suggests that polatuzumab vedotin with R-CHP may lead to improvements in health-related quality of life, although specific validated tools and effect sizes are not detailed in the document. The committee acknowledged the psychological burden of DLBCL and the potential for improved quality of life with effective treatment, supporting a moderate rating.
Supporting Domains
Safety and Adverse Effects
The safety profile of polatuzumab vedotin with R-CHP appears favorable, with adverse events being mostly manageable. The committee noted that the treatment’s tolerability is comparable to existing therapies, with no significant safety concerns raised that would undermine its overall value.
Comparator Selection
The treatment was compared against the appropriate standard of care, R-CHOP, in the POLARIX trial. The committee recognized that while the evidence was focused on patients with an IPI score of 2 to 5, this aligns with clinical practice and the marketing authorization, supporting the appropriateness of the comparator.
Patient Population and Subgroups
The trial population is broadly representative of the intended patient population with untreated DLBCL, specifically those with an IPI score of 2 to 5. The committee noted that while some subgroup analyses were exploratory, the core population was adequately covered, enhancing generalizability.
Care Pathway Integration
Polatuzumab vedotin with R-CHP can be integrated into existing treatment pathways with manageable adjustments. The committee indicated that the treatment aligns well with current clinical practices, requiring minimal changes to existing protocols.
Resource Use and Cost Implications
The resource implications of adopting polatuzumab vedotin with R-CHP are considered manageable, with the potential for cost savings due to its effectiveness in preventing disease progression. The committee’s conclusions regarding the cost-effectiveness support a favorable view on resource use.
Evidence Quality and Robustness
The evidence base is supported by a robust Phase 3 RCT (POLARIX) with a well-defined methodology. However, some uncertainties remain regarding overall survival data, which affects the robustness of the conclusions drawn. The committee acknowledged these limitations but still found the evidence acceptable.
Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding long-term survival estimates, the committee noted that the treatment addresses a significant unmet need in a high-burden disease. The context of the treatment’s potential benefits helps mitigate some of the uncertainties, leading to a favorable assessment.
